John J. Talley is an American medicinal chemist who was the lead chemist in the discovery of the COX-2 selective nonsteroidal anti-inflammatory drug celecoxib and a co-inventor of amprenavir, a protease inhibitor used to treat HIV infection.[1][2]
He earned his BA at the University of Northern Iowa and his PhD in chemistry from the University of Minnesota. From 1979 to 1986 he worked at the General Electric R&D center in Schenectady, New York then joined the Searle division of Monsanto, where he led the team that discovered celecoxib, as well as other marketed COX-2 inhibitors valdecoxib, parecoxib, and mavacoxib, as well as amprenavir which licensed by Searle to Vertex Pharmaceuticals.[2][3] In 2002 he was hired by Microbia to lead their antifungal drug discovery efforts.[4][1][5] He left the company in 2008.[6]
References
edit- ^ a b Langreth, Robert (June 23, 2003). "The Chemical Cobbler". Forbes.
- ^ a b "Dr. John Talley: 2001 St. Louis Awardee" (PDF). Chemical Bond. 52 (5). St. Louis Section, American Chemical Society: 2. May 2001. Archived from the original (PDF) on 15 April 2018.
- ^ "Press release: UNI alumni and friends honored at Distinguished Awards Celebration". UNI Foundation. November 18, 2015.
- ^ Withers, Melissa (September 22, 2004). "Drug hunters". Paradigm Magazine, Whitehead Institute.
- ^ McCarthy, Alice A. (February 2003). "Microbia" (PDF). Chemistry & Biology. 10 (2): 99–100. doi:10.1016/S1074-5521(03)00031-0. PMID 12618178.
- ^ "John J. Talley profile". Bloomberg. Retrieved 15 April 2018.